Quest Diagnostics Incorporated (DGX) : Traders are getting increasingly bearish on Quest Diagnostics Incorporated (DGX), as can be seen in the addition of short positions from 6,287,173 on Jul 29, 2016, to 6,474,226 on August 15, 2016. The net change in shorts is 187,053 shares, an increase of 3%. 8 days remain before the expiry. The 4.7% of outstanding short positions on the stock compared to its float, shows that traders expect the stock to fall from the current levels. The daily volume of the stock is 835,768. The short interest information was released on Wednesday Aug 24th after the market close.
Quest Diagnostics Incorporated (NYSE:DGX): The stock opened at $84.48 on Wednesday but the bulls could not build on the opening and the stock topped out at $84.75 for the day. The stock traded down to $83.34 during the day, due to lack of any buying support eventually closed down at $83.45 with a loss of -1.22% for the day. The stock had closed at $84.48 on the previous day. The total traded volume was 1,467,346 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Quest Diagnostics Inc, Britell Jenne K had sold 4,000 shares worth of $340,800 in a transaction dated August 10, 2016. In this transaction, 4,000 shares were sold at $85.2 per share.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.